Mental Health & Psychiatry Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Partners in Caring for Anxious Youth

This Phase 3 study is exploring whether combining cognitive behavioral therapy (CBT) with medication helps children and teens aged 7 to 17 who have anxiety disorders more than CBT alone. The trial focuses on common types of anxiety including separation anxiety, generalized anxiety, and social anxiety. If the combined approach proves better, it could lead to improved treatment plans that help young people feel less anxious and more supported over time.

Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings

This trial is testing a new virtual therapy platform called Teleo that aims to make psychotherapy more engaging and easier to access for children with anxiety and mood disorders. By offering an alternative to standard video calls, Teleo could help more children receive effective mental health support in a way that fits their needs. The results will show if this innovative approach works well in real-world clinical settings.

Sedation With Dexmedetomidine-esketamine Combination and Delirium in ICU Patients

This completed trial studied a sedation method using dexmedetomidine and esketamine for older patients recovering in intensive care after surgery. Delirium, a serious confused state, is common in these patients and can delay recovery. The findings may guide better sedation choices that reduce delirium, potentially improving hospital stays and long-term outcomes for older adults.

A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD

This study is testing a new once-daily pill called viloxazine extended-release for children and teens with attention deficit hyperactivity disorder (ADHD). If successful, it could offer a convenient medication option that helps manage symptoms such as inattention and hyperactivity. This may provide families and healthcare providers in South Korea with an additional tool for treating ADHD.

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

This Phase 2 trial is examining whether clemastine, a common antihistamine, can improve brain function and enhance antidepressant effects in older adults experiencing depression. Improving white matter in the brain may also help with memory and thinking problems often linked to depression. Positive results could lead to new ways to support mental health in late life.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.